The purpose of the Administration, Evaluation and Planning Core is to assure the coordination of the Dana Farber/Harvard Cancer Center (DF/HCC) Kidney Cancer SPORE components and to provide oversight and leadership of the scientific, administrative and fiscal aspects of the SPORE. The SPORE will take advantage of the Beth Israel Deaconess Medical Center's large and efficient administrative staff and its central Research Administration office. It will also work closely with the administrative office of the DF/HCC and integrate its administrative activities with that of the Cancer Center. Within the DF/HCC Kidney Cancer SPORE there are several layers of oversight and evaluation. Dr. Atkins, as SPORE Director, leads the Governance Committee and oversees all aspects of the SPORE. The Governance Committee, made up of senior members of the DF/HCC Kidney Cancer Program and patient advocates meets monthly to monitor the progress of Projects, Cores and Career Development and Developmental Research Programs and facilitate prompt decision-making. SPORE Co-PIs, Drs. Iliopoulos and Kaelin share responsibility with Dr. Atkins for coordinating the Developmental Project and Career Development Award activities, respectively, with Dr. Iliopoulos also serving as Co-leader of the DF/HCC Kidney Cancer Program. The SPORE has a strong Internal Advisory Board comprised of prominent members ofthe Harvard Medical School community and representing the participating institutions and major cancer research disciplines. An External Advisory Board has been in place for the past several years and will meet as a group in New England area during years two and four of the five-year funding cycle and as individuals at DF/HCC institutions during the other years. The responsibilities of this core are to: 1) Monitor research progress and plan for the future;2) Foster collaborative research within the SPORE and between SPOREs and other kidney cancer programs;3) Integrate the SPORE into the DF/HCC structure;4) Provide necessary resources and fiscal oversight;5) Promote rapid dissemination of significant research findings;6) Promote participation of minorities in kidney cancer research and treatment programs;7) Encourage new investigator participation in kidney cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA101942-09
Application #
8381285
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
9
Fiscal Year
2012
Total Cost
$169,897
Indirect Cost
$38,291
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
De Velasco, Guillermo; Je, Youjin; Bossé, Dominick et al. (2017) Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunol Res 5:312-318
Carey, Christopher D; Gusenleitner, Daniel; Lipschitz, Mikel et al. (2017) Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood 130:2420-2430
Kansy, Benjamin A; Concha-Benavente, Fernando; Srivastava, Raghvendra M et al. (2017) PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Res 77:6353-6364
Juneja, Vikram R; McGuire, Kathleen A; Manguso, Robert T et al. (2017) PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med 214:895-904
Ott, Patrick A; Hu, Zhuting; Keskin, Derin B et al. (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547:217-221
Zhang, Ying; Kurupati, Raj; Liu, Ling et al. (2017) Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell 32:377-391.e9
Abelin, Jennifer G; Keskin, Derin B; Sarkizova, Siranush et al. (2017) Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction. Immunity 46:315-326
Zhang, Yiqun; Kwok-Shing Ng, Patrick; Kucherlapati, Melanie et al. (2017) A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. Cancer Cell 31:820-832.e3
Zhou, Jun; Mahoney, Kathleen M; Giobbie-Hurder, Anita et al. (2017) Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunol Res 5:480-492
Akbay, Esra A; Koyama, Shohei; Liu, Yan et al. (2017) Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. J Thorac Oncol 12:1268-1279

Showing the most recent 10 out of 137 publications